ArticleLeukemia2010
JAK2 46/1 haplotype analysis in myeloproliferative neoplasms and acute myeloid leukemia.
Article in Leukemia, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- JAK2 V617F, MPL, and CALR mutations in essential thrombocythaemia and major thrombotic complications: a single-institute retrospective analysis.Pathology oncology research : POR · 2015Trial
- The JAK2 46/1 haplotype is a risk factor for myeloproliferative neoplasms in Chinese patients.International journal of hematology · 2012Trial
- The prognostic impact of germline 46/1 haplotype of Janus kinase 2 in cytogenetically normal acute myeloid leukemia.Haematologica · 2011Trial
- Characterization of JAK2V617F and the JAK2 46/1 germline haplotype in myeloproliferative neoplasms in a Saudi Arabian cohort: a case-based analysis.Frontiers in oncology · 2026Article
- Exploring hematological alterations and genetics linked to SNV rs10974944 in myeloproliferative neoplasms among Amazon patients.Scientific reports · 2024Article
- Essential thrombocythaemia progression to the fibrotic phase is associated with a decrease in JAK2 and PDL1 levels.Annals of hematology · 2022Article
- The Contribution ofInternational journal of molecular sciences · 2022Review
- Advances in germline predisposition to acute leukaemias and myeloid neoplasms.Nature reviews. Cancer · 2021Review
- The JAK2 GGCC (46/1) Haplotype in Myeloproliferative Neoplasms: Causal or Random?International journal of molecular sciences · 2018Review
- The role of genotypes that modify the toxicity of chemical mutagens in the risk for myeloproliferative neoplasms.International journal of environmental research and public health · 2015Article
- Association between JAK2 rs4495487 Polymorphism and Risk of Budd-Chiari Syndrome in China.Gastroenterology research and practice · 2015Article
- Distinct clinical characteristics of myeloproliferative neoplasms with calreticulin mutations.Haematologica · 2014Article
- Inherited predisposition to myeloproliferative neoplasms.Therapeutic advances in hematology · 2013Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
20811399What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.